Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives $13.00 Consensus Target Price from Analysts

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $13.00.

OBIO has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Orchestra BioMed in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Orchestra BioMed in a report on Thursday, May 14th. Piper Sandler reissued an “overweight” rating and set a $10.00 target price (up from $9.00) on shares of Orchestra BioMed in a research report on Tuesday, August 11th. Wall Street Zen downgraded shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Barclays increased their price objective on shares of Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th.

Insider Activity at Orchestra BioMed

In related news, insider Darren Sherman sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $4.09, for a total transaction of $61,350.00. Following the completion of the sale, the insider owned 1,154,327 shares of the company’s stock, valued at $4,721,197.43. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.50% of the stock is currently owned by insiders.

Institutional Trading of Orchestra BioMed

Large investors have recently modified their holdings of the stock. Simplify Asset Management Inc. acquired a new stake in Orchestra BioMed in the first quarter worth $932,000. 683 Capital Management LLC acquired a new position in shares of Orchestra BioMed during the fourth quarter valued at about $847,000. Cannon Global Investment Management LLC acquired a new position in shares of Orchestra BioMed during the first quarter valued at about $96,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Orchestra BioMed in the 4th quarter valued at about $38,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Orchestra BioMed in the 2nd quarter valued at about $91,000. Institutional investors and hedge funds own 53.20% of the company’s stock.

Orchestra BioMed Trading Up 19.9%

Shares of NASDAQ OBIO opened at $5.66 on Friday. The firm has a 50 day moving average price of $4.07 and a two-hundred day moving average price of $4.13. The stock has a market cap of $340.17 million, a P/E ratio of -6.66 and a beta of 0.50. Orchestra BioMed has a 52-week low of $2.20 and a 52-week high of $5.77. The company has a debt-to-equity ratio of 1.80, a quick ratio of 8.24 and a current ratio of 8.26.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.01. The company had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.14 million. Orchestra BioMed had a negative net margin of 184.60% and a negative return on equity of 149.61%. As a group, equities analysts forecast that Orchestra BioMed will post -1.53 EPS for the current year.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.